Helge Großhans, Ingo Büssing  Cancer Cell 

Slides:



Advertisements
Similar presentations
Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation Silvia Di Agostino,
Advertisements

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr
PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment Yongping Crawford, Ian.
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.
The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
The Kinase-Independent, Second Life of CDK6 in Transcription
Unraveling the TWIST between EMT and Cancer Stemness
“Atypical” Regulation of Hedgehog-Dependent Cancers
Linking miRNA Regulation to BCR-ABL Expression: The Next Dimension
“Ring-Fencing” BRCA1 Tumor Suppressor Activity
Metastasis gets site specific
The Ids Have It Cancer Cell
Mutant p53 gain of function: The NF-Y connection
Ujjawal H. Gandhi, William Senapedis, Erkan Baloglu, Thaddeus J
Three Down and One To Go: Modeling Medulloblastoma Subgroups
New Hope for a MicroRNA Therapy for Liver Cancer
The BRCA1 suppressor hypothesis: An explanation for the tissue-specific tumor development in BRCA1 patients  Stephen J Elledge, Angelika Amon  Cancer.
George-Lucian Moldovan, Alan D. D'Andrea  Cancer Cell 
Annapoorni Rangarajan, Sue J. Hong, Annie Gifford, Robert A. Weinberg 
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
“Ring-Fencing” BRCA1 Tumor Suppressor Activity
DAISY: Picking Synthetic Lethals from Cancer Genomes
Volume 26, Issue 1, Pages 1-2 (July 2014)
Eun-Jung Jung, George A. Calin  Cancer Cell 
The Wind God Promotes Lung Cancer
Kidney Cancer: Now Available in a New Flavor
Volume 18, Issue 4, Pages (October 2010)
SIRT6 Puts Cancer Metabolism in the Driver’s Seat
Volume 13, Issue 1, Pages 1-2 (January 2008)
A Radical Role for p38 MAPK in Tumor Initiation
Rémy Denzler, Markus Stoffel  Molecular Cell 
Volume 131, Issue 1, Pages (October 2007)
MicroRNA Regulation of Stem Cell Fate
BMP Signaling Goes Posttranscriptional in a microRNA Sort of Way
Bringing IDH into the Fold
Learning the ABCs of Melanoma-Initiating Cells
Volume 6, Issue 3, Pages (September 2004)
MicroRNAs and Parallel Stem Cell Lives
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
HMGA2, MicroRNAs, and Stem Cell Aging
The great MYC escape in tumorigenesis
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
Inflammation Joins the “Niche”
Volume 133, Issue 1, Pages (April 2008)
MicroRNAs and Viral Infection
RalGDS comes of age Cancer Cell
Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy  Laurence Blavier, Yves A. DeClerck 
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
BMPing Off Glioma Stem Cells
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
Volume 14, Issue 4, Pages (October 2008)
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Marta Chesi, P. Leif Bergsagel  Cancer Cell 
All Roads Lead to the Ribosome
Co-opted integrin signaling in ErbB2-induced mammary tumor progression
Learning the ABCs of Melanoma-Initiating Cells
There's a Time and a Place for MYCN
Volume 17, Issue 2, Pages (February 2010)
New Myc-anisms for DNA Replication and Tumorigenesis?
Mind the IQGAP Cancer Cell
Volume 12, Issue 6, Pages (December 2007)
Kidney Cancer: Now Available in a New Flavor
Anthony N. Imbalzano, Stephen N. Jones  Cancer Cell 
Knocking the Wnt out of the Sails of Leukemia Stem Cell Development
IL-9 by INFERence Immunity
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Presentation transcript:

MicroRNA Biogenesis Takes Another Single Hit from Microsatellite Instability  Helge Großhans, Ingo Büssing  Cancer Cell  Volume 18, Issue 4, Pages 295-297 (October 2010) DOI: 10.1016/j.ccr.2010.10.005 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 XPO5 Haploinsufficiency Impairs miRNA Biogenesis and Promotes Tumorigenesis (A) Schematic depiction of the miRNA biogenesis pathway. Some relevant proteins are indicated. XPO5 mediates nuclear export of pre-miRNAs in a complex with RanGTP; this complex disassembles in the cytoplasm upon hydrolysis of GTP to GDP. A bolt marks haploinsufficient tumor suppressors, which include XPO5. (B) Functional pre-miRNA export in XPO5+/+ wild-type cells sustains the mature miRNA levels that are required to control cell differentiation and proliferation. Impaired pre-miRNA export in XPO5mut/+ heterozygous mutant cells depletes mature miRNAs and is tumorigenic but can be overcome by expression of additional wild-type XPO5. This, and the fact that partial depletion of XPO5 by RNAi mimics XPO5mut/+ heterozygosity, is consistent with haploinsufficiency rather than mutant gain of function causing the defects. Cancer Cell 2010 18, 295-297DOI: (10.1016/j.ccr.2010.10.005) Copyright © 2010 Elsevier Inc. Terms and Conditions